Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia.
- Author:
Ge SHEN
1
;
San-tai SONG
;
Ze-fei JIANG
;
Shou-geng BIAN
;
Guang-ru XIE
;
Ya-jie WANG
;
Jie-jun WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; adverse effects; therapeutic use; Diphosphonates; adverse effects; therapeutic use; Female; Humans; Hypercalcemia; drug therapy; etiology; Imidazoles; adverse effects; therapeutic use; Male; Middle Aged; Neoplasms; complications; Safety
- From: Chinese Journal of Oncology 2005;27(10):632-634
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect and safety of zoledronic acid (Zoledex) in patients with cancer-induced hypercalcemia.
METHODSSeventeen patients with cancer-induced hypercalcemia (corrected blood calcium > 2.70 mmol/L) were treated intravenously by 4 mg zoledex within 15 minutes on the first day. The corrected blood calcium was observed every 4 days in the following 28 days.
RESULTSThe response rate was 94.1% (16/17). The mean corrected blood calcium became normal after the first dose of zoledex (P < 0.01). The lowest value was found on the fourteenth day after treatment. The main side effects consisted of fever (29.4%, 5/17), hypocalcemic tetany (11.8%, 2/17) and arythmia (5.9%, 1/17).
CONCLUSIONZoledex is effective and safe in the treatment of patient with cancer-induced hypercalcemia.
